Molecular Stock Forum

$Molecular (MOLN.US)$
Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going
Molecular Partners (MOLN) reported its Q3 2024 interim results, highlighting progress across its portfolio. The company's Radio-DARPin candidate MP0712 is preparing for clinical entry in 2025. The company strengthened its agreement with Orano Med to co-develop four 212Pb-based Radio-DARPin candidat...

$Molecular (MOLN.US)$
Molecular Partners and Orano Med Strengthen Agreement to Co-Develop 212Pb-Based Radio-DARPin Therapeutics
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) has strengthened its co-development agreement with Orano Med for 212Pb-based Radio-DARPin Therapeutics. The revised agreement now includes four Radio-DARPin programs, with each company holding commercialization rights to two programs. Molecular Partners retains rights to the first program, MP0712 targeting DLL3, and gai...

$Molecular (MOLN.US)$
Molecular Partners and Orano Med Present Additional Positive Preclinical Data Supporting DLL3 Targeting Radio-DARPin Therapeutic Candidate MP0712 at EANM 2024
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) and Orano Med presented positive preclinical data for their Radio-DARPin Therapeutic (RDT) candidate MP0712 at the EANM Congress 2024. MP0712, targeting delta-like ligand 3 (DLL3), showed:
- Dose-dependent efficacy with a favorable safety profile
- Attractive tumor to...

$Molecular (MOLN.US)$ $JE Cleantech Holdings Limited (JCSE.US)$ $iSpecimen (ISPC.US)$ $VSee Health (VSEE.US)$ $Spirit Airlines (SAVE.US)$ $Aptevo Therapeutics (APVO.US)$ $Inspire Veterinary Partners (IVP.US)$ $Siyata Mobile (SYTA.US)$ $BioVie (BIVI.US)$ $GRI Bio (GRI.US)$ $Genprex (GNPX.US)$
📊⚡️📊

$Molecular (MOLN.US)$
Molecular Partners Announces Upcoming Top-Rated Oral Presentation on MP0712, a ²¹²Pb-labeled Radio-DARPin Therapeutic targeting DLL3 for Small Cell Lung Cancer co-developed with Orano Med, at EANM 2024
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) announced an upcoming presentation on MP0712, a ²¹²Pb-labeled Radio-DARPin Therapeutic (RDT) targeting DLL3 for Small Cell Lung Cancer, at the European Association of Nuclear Medicine (EANM) Congress in Hamburg, Germany, Octo...

$Molecular (MOLN.US)$  Will be watching to see what happens. They are pretty healthy books but aren't terribly close to market on anything yet? 🤔

$Neo-Concept International (NCI.US)$ Uptrending. Borrow rate doubled Friday. Breakout is at .90. Trend is based on acquisition news.
$Boqii (BQ.US)$ Short sellers are slowly covering until breakout at .67 it appears. After that resistance is at 1.00 and 2.22.
$Senstar Technologies (SNT.US)$ No resistance will move up until shorts decide to pull it back.
$Molecular (MOLN.US)$  Same as SNT.
$Borealis Foods (BRLS.US)$ Highest borrow rate on market. Will run very soon and reach...

$Molecular (MOLN.US)$
👍👍👍

$Molecular (MOLN.US)$
Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024
Molecular Partners has presented the final data from its Phase 1 trial of MP0317, a CD40 agonist, at the ASCO 2024 Annual Meeting. The study included 46 patients with advanced solid tumors and showcased favorable safety and promising efficacy. MP0317 was shown to localize within the tumor microenvironment (...

$Molecular (MOLN.US)$
NEWS
Molecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533’s Proposed Mechanism of Action 
Preclinical data shows preferential T cell-mediated killing of AML cells by MP0533 while sparing healthy cells.
MP0533 induces tumor regression and T-cell activation without systemic adverse effects.
The data supports the clinical development of MP0533 as a potential treatment for acute myeloid leukemia.
The ongoing Phase 1/2a clin...